Peripheral neuropathies after BRAF and/or MEK inhibitors treatment: A pharmacovigilance study

被引：0
作者：
Picca, A. [1 ]
Birzu, C. [1 ]
Berzero, G. [2 ]
Sanchez-Pena, P. [3 ]
Gaboriau, L. [4 ]
Vidil, F. [5 ]
Lenglet, T. [6 ]
Tafani, C. [7 ]
Ricard, D. [7 ]
Psimaras, D. [1 ]
Bihan, K. [8 ]
机构：
[1] Sorbonne Univ, Hop Univ 8 La Pitie Salpetriere Charles Foix, Inst Cerveau, AP HP,CNRS,Inserm,UMR S 1127,ICM, Paris, France
[2] IRCCS San Raffaele Sci Inst, Neurol Unit, Milan, Italy
[3] CHU Bordeaux, Pole Sante Publ, Serv Pharmacol Med, Bordeaux, France
[4] CHU Lille, Serv Pharmacol Med, Ctr Reg Pharmacovigilance, Lille, France
[5] Agence Natl Securite Medicament & Produits Sante, St Denis, France
[6] GH Pitie Salpetriere, AP HP, Dept Neurophysiol Clin, Paris, France
[7] Hop Instruct Armees Percy, Serv Sante Armees, Dept Neurol, Paris, France
[8] GH Pitie Salpetriere, AP HP, Dept Pharmacol, Ctr Reg Pharmacovigilance, Paris, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2022年 / 36卷
关键词：
neuropathy; polyradiculoneuropathy; BRAF inhibitors; MEK inhibitors; neurotoxicity; melanoma; pharmacovigilance; adverse events;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PS-089
引用
收藏
页码：139 / 140
页数：2
相关论文
共 50 条
  • [31] EFFECTIVE COMBINATION THERAPIES WITH MEK INHIBITORS FOR THE TREATMENT OF MUTANT-BRAF LUNG CANCERS
    Matti, Emmanuel
    Ramsdale, Rachel
    Rao, Aparna
    Mcarthur, Grant
    Ferrao, Petranel T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1067 - S1067
  • [32] Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors
    Devic, Perrine
    Amini-Adle, Mona
    Camdessanche, Jean-Philippe
    Dalle, Stephane
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 78 : 103 - 104
  • [33] Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma
    Khaddour, Karam
    Chicoine, Michael R.
    Huang, Jiayi
    Dahiya, Sonika
    Ansstas, George
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (12): : 1590 - 1595
  • [34] The "SWOT" of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?
    Nissan, Moriah H.
    Solit, David B.
    [J]. CURRENT ONCOLOGY REPORTS, 2011, 13 (06) : 479 - 487
  • [35] Integrating BRAF/MEK inhibitors into combination therapy for melanoma
    Smalley, K. S. M.
    Flaherty, K. T.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 100 (03) : 431 - 435
  • [36] Patient with stage IV melanoma with BRAF mutation - immunotherapy or BRAF and MEK inhibitors?
    Cybulska-Stopa, Bozena
    Ziobro, Marek
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (02): : 100 - 103
  • [37] BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
    Richman, Juliet
    Martin-Liberal, Juan
    Diem, Stefan
    Larkin, James
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (09) : 1285 - 1297
  • [38] The “SWOT” of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?
    Moriah H. Nissan
    David B. Solit
    [J]. Current Oncology Reports, 2011, 13 : 479 - 487
  • [39] A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition
    Buchbinder, Elizabeth I. I.
    Giobbie-Hurder, Anita
    Ott, Patrick A. A.
    [J]. INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 365 - 370
  • [40] A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition
    Elizabeth I. Buchbinder
    Anita Giobbie-Hurder
    Patrick A. Ott
    [J]. Investigational New Drugs, 2023, 41 : 365 - 370
12345